CA2709907C - Peptide derive du recepteur 3 de la neurotensine et utilisation dans le traitement de maladies psychiatriques - Google Patents

Peptide derive du recepteur 3 de la neurotensine et utilisation dans le traitement de maladies psychiatriques Download PDF

Info

Publication number
CA2709907C
CA2709907C CA2709907A CA2709907A CA2709907C CA 2709907 C CA2709907 C CA 2709907C CA 2709907 A CA2709907 A CA 2709907A CA 2709907 A CA2709907 A CA 2709907A CA 2709907 C CA2709907 C CA 2709907C
Authority
CA
Canada
Prior art keywords
peptide
trek
mice
depression
propeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2709907A
Other languages
English (en)
French (fr)
Other versions
CA2709907A1 (fr
Inventor
Jean Mazella
Olivier Petrault
Marc Borsotto
Catherine Heurteaux
Catherine Widmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Nice Sophia Antipolis UNSA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Nice Sophia Antipolis UNSA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Nice Sophia Antipolis UNSA filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CA2709907A1 publication Critical patent/CA2709907A1/fr
Application granted granted Critical
Publication of CA2709907C publication Critical patent/CA2709907C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2709907A 2007-12-21 2008-12-18 Peptide derive du recepteur 3 de la neurotensine et utilisation dans le traitement de maladies psychiatriques Active CA2709907C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07291602A EP2077278A1 (fr) 2007-12-21 2007-12-21 Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
EP07291602.6 2007-12-21
PCT/FR2008/001784 WO2009103898A1 (fr) 2007-12-21 2008-12-18 Peptide derive du recepteur 3 de la neurotensine et utilisation dans le traitement de maladies psychiatriques

Publications (2)

Publication Number Publication Date
CA2709907A1 CA2709907A1 (fr) 2009-08-27
CA2709907C true CA2709907C (fr) 2016-11-08

Family

ID=39304741

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2709907A Active CA2709907C (fr) 2007-12-21 2008-12-18 Peptide derive du recepteur 3 de la neurotensine et utilisation dans le traitement de maladies psychiatriques

Country Status (7)

Country Link
US (1) US8252748B2 (https=)
EP (2) EP2077278A1 (https=)
JP (1) JP5487117B2 (https=)
AT (1) ATE535543T1 (https=)
CA (1) CA2709907C (https=)
ES (1) ES2377489T3 (https=)
WO (1) WO2009103898A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2077278A1 (fr) * 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
US10251937B2 (en) 2014-01-27 2019-04-09 Medincell Retro-inverso analogs of spadin display increased antidepressant effects
CA3006313C (en) 2015-11-24 2020-02-11 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
FR3057267A1 (fr) 2016-10-11 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - Procede de diagnostic/determination de l'efficacite de traitement de la depression
FR3057266B1 (fr) * 2016-10-11 2021-05-21 Centre Nat Rech Scient Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression
WO2021078833A1 (en) * 2019-10-22 2021-04-29 Genethon Chimeric polypeptides and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511233A (ja) * 1998-01-27 2002-04-16 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｔｒｅｋ１様の２孔カリウムチャネル
AU2003287930A1 (en) * 2002-12-20 2004-07-14 Neuronicon Aps Modulation of activity of neurotrophins
EP2077278A1 (fr) * 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques

Also Published As

Publication number Publication date
ATE535543T1 (de) 2011-12-15
ES2377489T3 (es) 2012-03-28
US20110237515A1 (en) 2011-09-29
EP2077278A1 (fr) 2009-07-08
JP2011505864A (ja) 2011-03-03
WO2009103898A1 (fr) 2009-08-27
JP5487117B2 (ja) 2014-05-07
EP2229408B1 (fr) 2011-11-30
CA2709907A1 (fr) 2009-08-27
EP2229408A1 (fr) 2010-09-22
US8252748B2 (en) 2012-08-28

Similar Documents

Publication Publication Date Title
Verkhratsky et al. Physiology of astroglia
CA2709907C (fr) Peptide derive du recepteur 3 de la neurotensine et utilisation dans le traitement de maladies psychiatriques
Ambrogini et al. Morpho-functional characterization of neuronal cells at different stages of maturation in granule cell layer of adult rat dentate gyrus
Koert et al. Functional implications of neurotransmitter expression during axonal regeneration: serotonin, but not peptides, auto-regulate axon growth of an identified central neuron
Przyborski et al. Developmental regulation of MAP2 variants during neuronal differentiation in vitro
TWI582234B (zh) 從人類滋養層幹細胞中生成神經幹細胞
CA2322055C (fr) Nouvelle famille de canaux potassium de mammiferes mecanosensibles et actives par les acides gras polyinsatures et leur utilisation notamment pour le criblage de drogues
Yoshimura et al. Roles of 5-HT1A receptor in the expression of AMPA receptor and BDNF in developing mouse cortical neurons
EP3526244B1 (fr) Peptides dérivés du propeptide ntsr3 et leur utilisation dans le traitement de la dépression
Xu et al. Nuclear localization of Cav2. 2 and its distribution in the mouse central nervous system, and changes in the hippocampus during and after pilocarpine‐induced status epilepticus
Fitzakerley et al. Expression of Shal potassium channel subunits in the adult and developing cochlear nucleus of the mouse
CA3039273C (fr) Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression
Fischer et al. The maturation of photoreceptors in the avian retina is stimulated by thyroid hormone
Poletaeva et al. Audiogenic seizures-biological phenomenon and experimental model of human epilepsies
Srinivasan Loss of Multiple PDZ domain containing protein has sensory and cognitive consequences
Achicallende Urcaregui Ultrastructural and physiological studies on the cannabinoid CB1 receptor localized in astroglia.
FR3057266A1 (fr) Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression
FR2850397A1 (fr) Methode pour identifier des composes biologiquement actifs dans le traitement de la depression
Ichimura et al. 3D Morphological Processes of Foot Process Efface-ment Revealed by FIB/SEM Tomography
Rashid Contribution of Kv3 potassium channels to signal processing by electrosensory neurons
Etchepare Role of glutamate N-Methyl-D-Aspartate receptor surface trafficking in the firing pattern of midbrain dopaminergic neurons
Márquez Regulation of dystrophin Dp71 during Müller glial cells edema in mouse retina
Guilani Modulation of amphetamine-induced behaviors in mice by the atypical vesicular glutamate transporter type 3 (VGLUT3)
FR2970869A1 (fr) Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau post-transcriptionnel
Steinhäuser et al. 10 Astrocytes in Epilepsy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131204

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260129

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20260307

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260307

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260408